Zynerba Pharmaceuticals Stock News

Harmony has already gotten approval for the drug to treat adults with excessive daytime sleepiness who have narcolepsy. Harmony's second-quarter revenue was up 25%, year over year.

In a stunning turn of the tables, beleaguered cannabinoid therapeutics developer Zynerba Pharmaceuticals (NASDAQ: ZYNE ) skyrocketed on Monday following an announcement early this morning of a buyout.

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) stock rocketed three-times higher as investors are set to pocket a bumper payday as Harmony Biosciences (NASDAQ:HRMY) agreed to buy the cannabinoid therapies

Shares of Zynerba Pharmaceuticals Inc. ZYNE, +0.89% jumped 300% premarket on Monday after Harmony Biosciences Holdings Inc. HRMY, -0.47% said it would acquire the cannabinoid therapy company in a deal

Zynerba (ZYNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

DEVON, Pa., June 20, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychia

DEVON, Pa, March 07, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychia

DEVON, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychi

Comprehensive data review suggests a central role for the endocannabinoid system (ECS) in neuronal development, cognitive function and in the pathogenesis of Fragile X syndrome (FXS)

Want to try a different approach? Tap five stocks with increasing P/E ratios. These include CuriosityStream (CURI), Root (ROOT), LendingClub (LC), Manitex International (MNTX) and Zynerba Pharmaceutic

Want to try a different approach? Tap five stocks with increasing P/E ratios.

RECONNECT initial screening visits are being adversely impacted by environmental factors, such as the “Tripledemic” (high rates of RSV, influenza and COVID-19); topline results now expected first

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has revised its timeline for releasing topline results from its multiple-centre Phase 3 RECONNECT trial, which sees Zygel administered to children and adolesc

Zygel™ achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) said it has presented a poster at the 61st annual meeting of the American College of Neuropsychopharmacology, being held December 4-7, 2022 in Phoenix, Arizo